Our goal is to become the leader in new therapeutic development to safely treat autoimmune and inflammatory diseases, infectious diseases, as well as combination immunotherapy for cancer treatment.
Numerous animal and pre-clinical model studies have shown Orynotides to be promising agents for several clinical indications, and the stability, safety profile, and biocompatibility of these cyclic peptides make them a valuable platform for drug development.
With the successful completion of our Phase 1B trial for the Treatment of Rheumatoid Arthritis (A Randomized, Double-blind, Vehicle Controlled, Repeat Dose Comparative Phase 1b Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ORTD 1 in Rheumatoid Arthritis Patients with Mild Disease Managed with DMARDs), the systemic safety profile of the first Orynotide therapeutic drug candidate has been validated.
303 Twin Dolphin Drive
Suite 600 – #1320
Redwood City, CA 94065